PROK · Prokidney Corp.
$1.63
-0.10 (-5.52%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current operating plan, we do not believe our existing cash and cash equivalents and marketable securities as of June 30, 2026, will be sufficient to fund our obligations for the 12 months following the issuance of the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q on August 10, 2026. Accordingly, substantial doubt exists about our ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued.”View the 10-Q filed Aug 10, 2026
Market Cap
$483.72M
Shares
302.32M
Volume · Oct 5
507.97K
Avg daily vol (3M)
1.31M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.72
Open$1.72
Day$1.66–1.75
52W close$1.33–3.30
Avg vol 30d1.5M
Short int21.4M · 7.1% float · 19.0d
Short vol76%
Last earningsMay 10, 2024
DataJun 2021–Oct 2026
Filing10-Q · Aug 10
Up next
filed Aug 10, 2026
call held Nov 14, 2023
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$818,000
Trailing 12 months
Net income (TTM)
−$84.16M
Trailing 12 months
Revenue growth YoY
-32.1%
Year over year
Operating margin
-21,664.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-33.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$74.87M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-38.1%
Trailing year
Short interest
7.1%
Latest settlement · 19.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
+2%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
20%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−10%
trailing
6-month return
−12%
trailing
YTD return
−23%
this year
Relative strength
−24%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +22 funds added
Insider flow
Distributing
Net -$1.1M over 90 days · 100% sells
Short interest
Rising
7.09% of float · ▲ +3.4% MoM · 19.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
71 holders — mid 5-yr range
Squeeze score
80
high risk · 0–100
Fundamentals
Revenue growth
+1075%
Y/Y
Free cash flow
$-135.3M
Quant / Vol
risk profile
Volatility
72%
annualized · 1-yr
Max drawdown
−60%
past year
ATR
6.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
+2%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
20%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +22 funds added
Insider flow
Distributing
Net -$1.1M over 90 days · 100% sells
Short interest
Rising
7.09% of float · ▲ +3.4% MoM · 19.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
71 holders — mid 5-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 20%
Range high $3
vs 200-day avg -10%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PROK
this stock
Prokidney Corp.
|
$483.72M | -23.2% | +1075.0% | — | 7.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PROK | +7.5% | -10.4% | -11.8% | +3.6% | -23.2% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +7.7% | -10.0% | -24.0% | +2.7% | -36.1% |